InsiderTrades

Form 4 for ACRS Aclaris Therapeutics, Inc.

Accepted 2024-12-03 00:00:00 ET · period of report 2024-12-01 · accession 0001415889-24-028074 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-12-03 2024-12-01 ACRS Walker Neal INTERIM CEO, Dir M - OptEx — +9,466 1.39M +0.7% —
D 2024-12-03 2024-12-01 ACRS Walker Neal INTERIM CEO, Dir F - Tax $4.07 -2,721 1.38M -0.2% -$11.1K
D 2024-12-03 2024-12-01 ACRS Walker Neal INTERIM CEO, Dir M - OptEx $0.00 -9,466 47.3K -17% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-12-01 M A 9,466 — 1,385,854 D — — (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
2 Common Common Stock 2024-12-01 F D 2,721 $4.07 1,383,133 D — —
3 Derivative Restricted Stock Units 2024-12-01 M D 9,466 $0.00 47,334 D — · — to — 9,466 Common Stock (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. (F3) The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO.